Trial 4K-16-3


A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared with Everolimus in the Treatment of Adult Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma that Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments:
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Sarmad Sadeghi, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Lagrimas Ilagan, D.M., Amanda Luna, D.M., Charis Barg, Coordinator, Bartolo Santos, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.